Compare SkyWest Inc (SKYW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SkyWest Inc vs TG Therapeutics Inc — how do they compare? SkyWest Inc trades at $107.89 (market cap $4.19B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| SKYW | TGTX | |
|---|---|---|
Market Cap | $4.19B | $7.64B |
Sector | Technology | Health |
52-Week High | $123.72 | $59.06 |
52-Week Low | $78.40 | $26.94 |
Enterprise Value | $5.97B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SkyWest (SKYW) trades at $107.23, down 0.41% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows solid fundamentals with a P/E of 10.72 and net income margin of 9.78%, though Q2 2026 earnings missed estimates. Recent news highlights executive stock sales amid company buybacks, while analyst consensus remains positive with a $109.33 price target. Cash flow improved in 2026 to a net positive $33 million from a $105 million deficit in 2025.
The outlook for SKYW is cautiously optimistic, supported by undervalued metrics and bullish analyst ratings, but risks include earnings volatility and insider selling. Investment opportunity lies in its low valuation and operational cash flow growth, though investors should monitor fuel cost pressures and competitive dynamics in the airline industry.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
